AbbVie Files US, Europe Applications For Skyrizi In Psoriatic Arthritis

by Vandana Singh, Benzinga Editor

April 7, 2021 10:42 AM | 1 min read | Make a Comment

AbbVie Inc ABBV has submitted marketing applications to the FDA and European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab-rzaa, 150 mg) for the treatment of adults with active psoriatic arthritis.
In the Phase 3 KEEPsAKE-1 and KEEPsAKE-2 studies, Skyrizi demonstrated significant improvements in disease activity, skin clearance, and physical function at week 24 versus placebo.
Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
Price Action: ABBV shares were down 0.28% at $105.09 during market trading hours on the last check Wednesday.

Posted In: Biotech News Health Care FDA General Arthritis Briefs European Medicines Agency (EMA)

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.